1274results about How to "Good for weight loss" patented technology

An intragastric balloon and method of adding and/or removing fluid therefrom are disclosed. The intragastric balloon includes a shell, a grasping tab, and a self-sealing portion. A gastroscopic instrument which includes a grasping tool is inserted into the stomach of a patient and used to grasp the grasping tab located on the surface of the shell. Using the grasping tool, the intragastric balloon is securely fastened to the gastroscopic instrument. A filling instrument, such as a needle, is advanced through the self-sealing portion of the shell for the filling or deflating of the intragastric balloon. After inflation or deflation is complete, the filling instrument is then withdrawn from the balloon and the gastroscopic instrument withdrawn from the stomach.

The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB₁ and/or CB₂ receptor. Preferably both the inverse agonist of the CB₁ and/or CB₂ receptor and the neutral antagonist of the CB₁ and/or CB₂ receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).

An improved ultra-high fiber supplement that promotes satiety, caloric reduction, and weight loss. The supplement comprises guar, oat, psyllium, locust bean gum, pectin, green tea, multi-anthocyanadins, pyridoxine, and folic acid. The supplement can exist as a liquid, semi-solid, or solid comestible. It improves cardiovascular health and reduces cardiovascular inflammation and the risk of heart disease. The addition of antioxidants, including green tea, improves weight loss, and general and cardiovascular health. Also it reduces serum lipoprotein oxidation and risk of free-radical related diseases. Consumption of the supplement aids in reducing absorption and assimilation of ingested toxins. A method of providing an ultra-high fiber comestible that is highly palatable and can be used to supplement nutrition and to manage and prevent diet-related diseases is disclosed. Further embodiments increase fiber and other nutrients in the diet and helps manage and prevent all diet-related diseases.

The present invention is directed to an apparatus and method for treating obesity. A tube is positioned that passes through a patient's abdominal wall into the upper digestive system of the patient. The patient is allowed to carry out his/her everyday affairs including ingesting food. After the patient has ingested food, the food is extracted by pumping it out of the upper digestive system through the tube. The present invention is less invasive than current surgical procedures for reducing weight and allows patients to live a normal and active lifestyle without experiencing adverse side effects.

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The present invention discloses a fruit and vegetable probiotic tablet and a preparation method thereof. The fruit and vegetable probiotic tablet uses probiotic powders such as lactobacillus plantarum powder as the main raw material, and the preparation method scientifically mixes modified dietary fibers, fruit and vegetable powder, oligosaccharides, plant extracts, protein powder, tea leaf extracts and traditional Chinese medicine extracts and etc., thus improves the content of soluble celluloses which are of real significance for probiotic flora, enhances the physiological activity of celluloses, thereby increases the species of intestinal probiotic flora as well as significantly enhances the colonization ability and time of endogenous and exogenous probiotics in the human intestinal tracts, effectively inhibits the growth and reproduction of harmful intestinal bacteria, especially gram-negative bacteria, and fully regulates the composition of the intestinal probiotic flora. The prepared fruit and vegetable probiotic tablet has a high biological activity, a long human intestinal colonization time, and a significant weight loss effect, and is suitable for a wide range of people.

The present invention is drawn to combinations of pharmaceutical agents having similar chemical and/or pharmacological properties, wherein the combinations maximize the therapeutic effect of the drug while minimizing their adverse effects. The methods and compositions of the invention are particularly useful in the treatment of obesity and related conditions which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) or bupropion in combination with an anti-epileptic agent (e.g., topiramate, zonisamide), CB1 antagonists (e.g., rimonabant), or a 5HT_2C-selective serotonin receptor agonist, (e.g., lorcaserin) for the treatment of obesity and related conditions. The invention also features kits for use in the practice of these novel therapies.

An intragastric balloon having a built-in sensor. The sensor may be used to monitor pressure within the balloon shell, or outside of the shell in the stomach. The sensor may be used after deflation of the intragastric balloon to monitor the pressure through the intestinal tract as the balloon migrates therethrough. An apparatus for remote deflation of the balloon may be utilized to allow a physician to deflate the intragastric balloon without surgery. The pressure sensor may be provided in a valve of the intragastric balloon which separates from the balloon and migrates as a capsule through the intestinal tract to monitor conditions therein.

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Provided are compositions and methods for increasing diet induced thermogenesis. Typically, the compositions are comprised of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-valine and L-threonine.

This invention relates to compounds, compositions, and methods useful for modulating Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Stearoyl-CoA desaturase (SCD) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Stearoyl-CoA desaturase (SCD) genes.

A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue.

ACE-2 modulating compounds for the treatment of body weight disorders are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention discloses a wastewater treating microbial agent and a preparation method thereof. The microbial agent contains kocuriapalustris FSDN-A, arthrobactercreatinolyticus FDN-1, flavobacteriummizutaii FDN-2, paracoccusdenitrificans DN-3 and methylobacteriumphyllosphaerae SDN-3, wherein the collection register numbers of the five strains are respectively CGMCCNo.5061, CGMCCNo.3657, CGMCCNo.3659, CGMCCNo.3658 and CGMCCNo.3660. The microbial agent can achieve removal of ammonia nitrogen, total nitrogen and CODcr in the same reactor, has a good wastewater treatment effect, and can achieve short-cut nitrification and denitrification or simultaneous nitrification and denitrification while removing COD. Kocuriapalustris FSDN-A can utilize the two nitric oxides including nitrite nitrogen and nitric nitrogen, can ensure thorough denitrification of a wastewater treatment system, is slow in appreciation in the process of competing for substrates, is favorable for reduction of sludge, and further widens the application range of the microbial agent.

A computer program, method, and system for dynamically and interactively providing nutrition content information for consumables such that a user may monitor, tailor, plan, and review their intake thereof in light of a health-related interest or concern, such as, for example, weight-loss, food allergies, or diabetes or other nutrition affected illnesses or disabilities. Consumables are categorized and displayed in lists associated with an appropriate color to draw attention to relative nutrition content and to facilitate quicker and easier evaluation of a consumable of interest. Summaries are provided of a user's actual intake in light of a pre-established target intake for a particular day. Detailed reports may be generated showing consumption over a user-specifiable time period.

The invention provides a dephosphorization and denitrification, mud decrement and phosphorus recovery integrated sewage treatment device and a method thereof. The method adopts processes of hydrolysis acidification, multilevel series contact aeration and dephosphorization and denitrification A<2>/O of continuous flow, and comprises the following steps that: a hydrolysis acidification unit is used to treat raw sewage and a little anaerobic phosphorus releasing sludge to realize conversion of VFA; clear solution rich in the VFA after hydrolyzed supplies rich carbon sources for a subsequent dephosphorization and denitrification A<2>/O unit to reinforce synchronous dephosphorization and denitrification; and low concentration phosphorus in the sewage is enriched in the anaerobic phosphorus releasing sewage by the excessive phosphorus absorption capability of a phosphate accumulating organism, and the minor part of phosphorus enriched sewage is drained to carry out chemical phosphorus solidification. The dephosphorization mode can significantly reduce sewage quantity of chemical dephosphorization, improve the utility ratio of a dephosphorizing medicament, reduce dosage of the medicament, has high phosphorous amount in the obtained chemical sludge, and realizes recycle of the middle and low concentration phosphorus in urban sewage by the mode of non residue sludge under a condition of low cost. Sludge decrement can be realized through biofacies separation of a multilevel series contact aeration tank and the function of microorganism predation grade by grade.

The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below:

(R²)-A¹-A²-A³-A⁴-A⁵-A⁶-A⁷-A⁸-A⁹-A¹⁰-A¹¹-A¹²-A¹³-A¹⁴-A¹⁵-A¹⁶-A¹⁷-A¹⁸-A¹⁹-A²⁰-A²¹-A²²-A²³-A²⁴-A²⁵-A²⁶-A²⁷-A²⁸-R¹

wherein the definitions of A¹ to A²⁸, R¹ and R² are provided for in the specification, with the exception that the N-terminal amino acid must be selected from the group consisting of Inp, 1-Apc and 4-Apc, the pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of said compound together with therapeutic and non-therapeutic uses thereof.

A structure that can be used as a gastric band (and that may also have other uses as an implant elsewhere in a patient) includes a plurality of magnetic elements in a serial array that can be implanted so that the array extends in a circumferential direction around the patient's stomach (or other body tissue structure in the patient). Circumferentially adjacent magnetic elements magnetically attract one another to apply radial pressure to the tissue structure encompassed by the array, but those elements can also move apart in response to sufficient outward pressure from the encompassed tissue structure and/or the contents of (e.g., food in) that tissue structure. When used as a gastric band, the device can provide resistance to excessive food intake, which can help promote weight loss.